Trials / Completed
CompletedNCT01115855
Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart Failure
The Effect Of Eplerenone Versus Placebo On Cardiovascular Mortality And Heart Failure Hospitalization In Japanese Subjects With Chronic Heart Failure
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 221 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 55 Years
- Healthy volunteers
- Not accepted
Summary
A study to compare the efficacy and safety of eplerenone in Japanese chronic heart failure patients with placebo.
Detailed description
The aim of this study was to show consistency with the EMPHASIS-HF trial (NCT00232180), which was defined as a HR of the primary endpoint of below 1.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eplerenone | Eplerenone 25 mg once every other day, 25mg once daily or 50 mg once daily |
| DRUG | Placebo | Placebo once daily or every once daily |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2015-09-01
- Completion
- 2015-09-01
- First posted
- 2010-05-04
- Last updated
- 2020-12-22
- Results posted
- 2016-10-27
Locations
54 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01115855. Inclusion in this directory is not an endorsement.